BDNF and Parkinson disease: Group 1 contained terms including MAPK, chemokine, neurotrophin pathways; Group 2 included synaptic plasticity mechanisms and calcium signaling; and Group 3 included neurodegenerative diseases (Alzheimer’s, Huntington’s, and Parkinson’s) and metabolic mechanisms (glycolysis/gluconeogenesis and oxidative phosphorylation).